Quantum Genomics is a biopharmaceutical company developing firibastat, a brain aminopeptidase A inhibitor for the treatment of hypertension and heart failure. Its mechanism is implicated in the 25% of patients resistant to treatment. The Phase IIb study in hypertension was recently very positive and the Phase IIb in heart failure should start in Q219.
Healthcare |
Flash note
Healthcare |
Update
Healthcare |
Initiation
Healthcare |
Update
Forecast net debt (€m)
N/A
Forecast gearing ratio (%)
N/A
% | 1M | 3M | 12M |
---|---|---|---|
Actual | 6.0 | 30.1 | (91.0) |
Relative | 8.0 | 27.4 | (92.2) |
52 week high/low | €4.0/€0.1 |
Edison Investment Research is terminating coverage on Quantum Genomics (ALQGC). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should now be considered redundant.
Y/E Dec | Revenue (€m) | EBITDA (€m) | PBT (€m) | EPS (c) | P/E (x) | P/CF (x) |
---|---|---|---|---|---|---|
2020A | 4.0 | (13.1) | (14.7) | (72.0) | N/A | N/A |
2021A | 6.2 | (14.9) | (15.4) | (58.0) | N/A | N/A |
2022E | N/A | N/A | N/A | N/A | N/A | N/A |
2023E | N/A | N/A | N/A | N/A | N/A | N/A |
thematic
Financials
thematic
Healthcare
thematic
Industrials
thematic
Financials
thematic
Energy & Resources
thematic
Healthcare
thematic
Healthcare
thematic
Metals & Mining
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources
thematic
Energy & Resources